Full text loading...
- ISSN: 1389-2002
- E-ISSN: 1875-5453
-
CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
- Source: Current Drug Metabolism, Volume 15, Issue 8, Oct 2014, p. 808 - 817
-
- 01 Oct 2014
Abstract
Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.
© Bentham Science Publishers